文献速递神经肿瘤

IMA950联合varlilumab疫苗促进低级别胶质瘤患者外周血效应记忆T细胞分化

A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas.
PubMed 文献 · Neuro Oncol · 2024-01-01

这项前瞻性随机先导研究评估IMA950多肽疫苗联合抗CD27抗体varlilumab在CNS WHO 2级低级别胶质瘤患者中的安全性和免疫反应;共纳入14例,未观察到方案限制性毒性,所有患者外周血抗IMA950 CD8+ T细胞反应显著增加,但切除肿瘤中未检测到IMA950反应性CD8+ T细胞。

要点

  • 联合varlilumab可促进外周血单核细胞中Th1效应记忆CD4+和效应记忆CD8+ T细胞分化,但肿瘤微环境中未见此效应。
  • 疫苗后所有患者外周血抗IMA950 CD8+ T细胞反应显著增加,但切除肿瘤中未检测到IMA950反应性CD8+ T细胞。
  • 研究未观察到方案限制性毒性;作者认为需进一步开发克服血肿瘤屏障的策略以提高低级别胶质瘤免疫治疗疗效。

核心结论

  • 包括varlilumab的联合免疫治疗耐受性良好,在外周血中诱导疫苗反应性T细胞扩增,但肿瘤中未检测到可检测的反应。
  • 作者认为需进一步开发克服血肿瘤屏障的策略,以提高低级别胶质瘤患者的免疫治疗疗效。

研究设计与样本

  • 前瞻性、随机先导研究,评估多肽IMA950疫苗联合激动性抗CD27抗体varlilumab在CNS WHO 2级低级别胶质瘤患者中的安全性和免疫反应。
  • 患者随机接受IMA950+poly-ICLC联合varlilumab(第1组)或IMA950+poly-ICLC(第2组)术前治疗,随后接受辅助疫苗。
  • 共14例符合条件的患者入组;4例接受术前疫苗但因切除肿瘤诊断为高级别而被排除于术后疫苗之外。

主要发现

  • 未观察到方案限制性毒性。
  • 所有患者疫苗后外周血抗IMA950 CD8+ T细胞反应显著增加,但切除肿瘤中未检测到IMA950反应性CD8+ T细胞。
  • 质谱流式分析显示,加入varlilumab促进外周血单核细胞中T辅助1型效应记忆CD4+和效应记忆CD8+ T细胞分化,但肿瘤微环境中未见此效应。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者在结论中指出,需进一步开发克服血肿瘤屏障的策略以提高低级别胶质瘤免疫治疗疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Central nervous system (CNS) WHO grade 2 low-grade glioma (LGG) patients are at high risk for recurrence and with unfavorable long-term prognosis due to the treatment resistance and malignant transformation to high-grade glioma. Considering the relatively intact systemic immunity and slow-growing nature, immunotherapy may offer an effective treatment option for LGG patients. METHODS: We conducted a prospective, randomized pilot study to evaluate the safety and immunological response of the multipeptide IMA950 vaccine with agonistic anti-CD27 antibody, varlilumab, in CNS WHO grade 2 LGG patients. Patients were randomized to receive combination therapy with IMA950 + poly-ICLC and varlilumab (Arm 1) or IMA950 + poly-ICLC (Arm 2) before surgery, followed by adjuvant vaccines. RESULTS: A total of 14 eligible patients were enrolled in the study. Four patients received pre-surgery vaccines but were excluded from postsurgery vaccines due to the high-grade diagnosis of the resected tumor. No regimen-limiting toxicity was observed. All patients demonstrated a significant increase of anti-IMA950 CD8+ T-cell response postvaccine in the peripheral blood, but no IMA950-reactive CD8+ T cells were detected in the resected tumor. Mass cytometry analyses revealed that adding varlilumab promoted T helper type 1 effector memory CD4+ and effector memory CD8+ T-cell differentiation in the PBMC but not in the tumor microenvironment. CONCLUSION: The combinational immunotherapy, including varlilumab, was well-tolerated and induced vaccine-reactive T-cell expansion in the peripheral blood but without a detectable response in the tumor. Further developments of strategies to overcome the blood-tumor barrier are warranted to improve the efficacy of immunotherapy for LGG patients.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Saijo A, Ogino H, Butowski NA, et al. A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas. Neuro Oncol. 2024. PMID: 37758193. doi:10.1093/neuonc/noad185

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。